| Prostate Cell News 8.12 March 31, 2017 | |
|
|
|
|
TOP STORYResearchers evaluated untreated and ipilimumab-treated tumors from patients in a presurgical clinical trial. Levels of the PD-L1 and VISTA inhibitory molecules increased on independent subsets of macrophages in treated tumors. Their data suggests that VISTA represents another compensatory inhibitory pathway in prostate tumors after ipilimumab therapy. [Nat Med] Abstract | Press Release |
|
|
|
|
|
|
|
PUBLICATIONS(Ranked by impact factor of the journal)LABORATORY RESEARCHScientists discovered a fundamental role of S-phase protein kinase 2 (Skp2) in the formation and progression of castration-resistant prostate cancer. In a transgenic adenocarcinoma mouse prostate model, Skp2 depletion lead to a profound repression of prostate tumor growth and distal metastasis and substantially prolonged overall survival. [Oncogene] Abstract Mechanotransduction-Induced Reversible Phenotypic Switching in Prostate Cancer Cells Researchers demonstrated that culturing cells in different physical environments, stiff, soft, or suspension, induced a phenotypic switch in prostate cancer cells via mechanotransduction. The mechanosensitive phenotypic switching in prostate cancer cells was sustainable yet reversible even after long-term culture, demonstrating the impact of mechanical signals on prostate cancer cell phenotypes. [Biophys J] Abstract The authors observed that both androgen receptor positive and androgen receptor-negative prostate cancer cells differentiate into a neuroendocrine (NE) phenotype upon treatment with Dovitinib. The NE differentiation was also observed when mice harboring PC3-xenografted tumors were systemically treated with Dovitinib. [Transl Oncol] Full Article Scientists examined the potential use of multi-drug loaded micelles for prostate cancer treatment in preclinical models including cell line and mouse models for prostate cancers with Pten deletions. In vitro growth inhibition of prostate cancer cells was greater when all three drugs were used in combination compared to each individual drug, and packaging the drugs into micelles enhanced the cytotoxic effects. [PLoS One] Full Article SU6668 Modulates Prostate Cancer Progression by Downregulating MTDH/AKT Signaling Pathway Investigators found that SU6668 inhibited the proliferation and invasion of prostate cancer cells. Functional studies also demonstrated that SU6668 inhibited epithelial-mesenchymal transition in DU145 and LNCap cells. [Int J Oncol] Abstract | Full Article (Download) Researchers functionalized multi-walled carbon nanotubes by conjugating an antibody against prostate-specific membrane antigen. Their in vitro studies using prostate-specific membrane antigen-positive LNCaP prostate cancer cells, they effectively demonstrated cell ablation of >80% with a single 30-second exposure to a 2.7-W, 532-nm laser for the first time without bulk heating. [Tumour Biol] Full Article Down-Regulation of E-Cadherin Enhances Prostate Cancer Chemoresistance via Notch Signaling The authors explored the association between epithelial-to-mesenchymal transition (EMT) and chemoresistance in prostate cancer (PCa) as well as whether changing the expression of E-cadherin would affect PCa chemoresistance. Chemoresistant PC3-TxR and DU145-TxR cells exhibited an invasive and metastatic phenotype that associated with EMT, including the down-regulation of E-cadherin and up-regulation of Vimentin, Snail, and N-cadherin, compared with that of parental PC3 and DU145 cells. [Chin J Cancer] Full Article CLINICAL RESEARCHInvestigators reported the final results on treatment outcomes of a randomized trial comparing conventional and hypofractionated radiotherapy in high-risk, organ-confined prostate cancer. Long-term findings showed that hypofractionated radiotherapy failed the intent of either reducing physician-assessed late toxicity or maintaining the same efficacy. [J Clin Oncol] Full Article The authors determined the efficacy of abiraterone acetate with prednisone in high-risk patients with metastatic prostate cancer with a suboptimal response to hormonal induction. In the Phase II study including 40 patients, 13% of the patients had a strong prostate-specific antigen response with combination abiraterone acetate plus prednisone therapy, and the median overall survival was longer than that of historical controls. [JAMA Oncol] Abstract |
|
|
|
|
|
|
|
REVIEWSResearchers jointly update the Cancer Care Ontario guideline on brachytherapy for patients with prostate cancer to account for new evidence. An Update Panel conducted a targeted systematic literature review and identified more recent randomized controlled trials comparing dose-escalated external beam radiation therapy with brachytherapy in men with prostate cancer. [J Clin Oncol] Full Article Chimeric Antigen Receptors (CARs)–a Cell and Gene Therapy Perspective The targeting of CD19, a cell surface molecule expressed in the vast majority of leukemias and lymphomas, has been successfully translated in the clinic. CD19 CAR therapy is predicated on advances in genetic engineering, T cell biology, tumor immunology, synthetic biology, target identification, cell manufacturing sciences and regulatory compliance, central tenets of CAR therapy. The authors review two of these foundations—the genetic engineering approaches and cell types to which to apply them. [Mol Ther] Abstract Visit our reviews page to see a complete list of reviews in the prostate cell research field. |
|
|
|
|
SCIENCE NEWSGenomic Health, Inc. announced the presentation of new results from a large multi-center validation study, which confirmed that the Oncotype DX® Genomic Prostate Score™ is a strong independent predictor of metastases at ten years in prostate cancer patients across all National Comprehensive Cancer Network clinical risk groups. [Press release from Genomic Health, Inc. discussing research presented at the 32nd Annual European Association of Urology (EAU) Congress, London] Press Release GenomeDx’s Decipher Tests and Decipher GRID to be Featured in Multiple Presentations GenomeDx Biosciences announced that six abstracts featuring Decipher GRID® (Genomics Resource Information Database) and Decipher® Prostate Cancer Classifier tests will be presented. [Press release from GenomeDx Biosciences discussing research presented at the 32nd Annual European Association of Urology (EAU) Congress, London] Press Release Penn Studies Find Promise for Innovations in Liquid Biopsies From using fluid in the lungs to better understand the potential of immunotherapy treatments in lung cancer, to tracking circulating tumor cells in prostate cancer, to conducting RNA sequencing of cancer cell clusters from the blood of pancreatic cancer patients, to finding new ways to biopsy tissue from patients who may have esophageal cancer, a series of studies demonstrate the promise of new diagnostic methods. [Press release from Penn Medicine discussing research to be presented at the 2017 American Association for Cancer Research (AACR) Annual Meeting, Washington, D.C.] Press Release |
|
|
|
|
INDUSTRY NEWSSwedish Prostate Cancer Test to Be Introduced in Europe The new Stockholm3 test, which improves prostate cancer diagnosis, gets assistance from EIT Health for a faster introduction in Europe. In a first step the test will be clinically validated in Germany, the Netherlands and Belgium. The Stockholm3 test was developed by researchers at Karolinska Institutet. [Karolinska Institutet] Press Release Bezos Family Gives $35 Million to Fred Hutch Fred Hutch’s quest for cures was propelled forward with a $35 million gift from the Bezos family. It is the single largest philanthropic commitment to Fred Hutch in the center’s 41-year history. The Bezos family is offering this unprecedented gift to help Fred Hutch achieve its top strategic aim ― identifying and attracting more world-class talent to lead and propel the research priorities at the core of the Hutch’s new strategic plan. [Fred Hutchinson Cancer Research Center] Press Release | |
|
|
|
POLICY NEWSTrump Wants 2018 NIH Cut to Come from Overhead Payments The Trump administration could slash $5.8 billion from the 2018 budget of the National Institutes of Health, yet still fund as least as much research by eliminating overhead payments to universities and research institutions, Secretary of Health and Human Services Tom Price told lawmakers. [Science Insider] Editorial European Commission Considering Leap into Open-Access Publishing One of Europe’s biggest science spenders could soon branch out into publishing. The European Commission, which spends more than €10 billion annually on research, may follow two other big league funders, the Wellcome Trust and the Bill & Melinda Gates Foundation, and set up a “publishing platform” for the scientists it funds, in an attempt to accelerate the transition to open-access publishing in Europe. [ScienceInsider] Editorial Europe Says University of California Deserves Broad Patent for CRISPR The European Patent Office announced its “intention to grant a patent” to the University of California (UC) for its broad-based claims about the genome-editing tool popularly known as CRISPR. UC, on behalf of several parties, has been in a pitched battle with the Broad Institute of Cambridge, Massachusetts, over CRISPR patents, and the new decision marks a sharp departure from the position of the U.S. Patent and Trademark Office. [ScienceInsider] Editorial
|
|
EVENTSNEW Mitochondrial Biogenesis and Dynamics in Health, Disease and Aging Visit our events page to see a complete list of events in the community.
|
|
JOB OPPORTUNITIESNEW Scientist – Prostate Cancer Research (Dana-Farber Cancer Institute) NEW Postdoctoral Fellow – Cancer Biology (Northwestern University) Postdoctoral Fellow – Prostate Cancer (Johns Hopkins University) Postdoctoral Fellow – Prostate/Pancreatic Cancer (Medical College of Wisconsin) Postdoctoral Fellow – Prostate Cancer Research (Vancouver Prostate Center) PhD Student – Prostate Cancer Research (Vancouver Prostate Center) Faculty Position – Urologic Pathology (University of California Los Angeles) Postdoctoral Fellow – Computational Cancer Biology (European Molecular Biology Laboratory) Postdoctoral Research Fellow – Urological Cancers (Institute of Cancer Research) Postdoctoral Position – Genomics and Molecular Biology (The George Washington University) PhD Studentships – Translational Research Network for Prostate Cancer (University of Glasgow) Recruit Top Talent: Reach potential candidates by posting your organization’s career opportunities on the Connexon Creative Job Board at no cost.
|
|
|
Have we missed an important article or publication in Prostate Cell News? Click here to submit! Comments or suggestions? Submit your feedback here. |
|
|
